Artera Showcases Innovative AI Solutions for Cancer Treatment at ASCO 2026
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
Image: Businesswire
Artera will present several abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its multimodal artificial intelligence (MMAI) platform's effectiveness in breast and prostate cancer treatment decisions. The studies demonstrate MMAI's ability to enhance risk stratification and treatment decision-making for node-positive breast cancer and localized prostate cancer patients.
- 01Artera's studies include an oral presentation on MMAI's validation for node-positive HR+ breast cancer, focusing on chemotherapy benefit prediction.
- 02A poster presentation will compare MMAI's prognostic performance against the 21-gene Recurrence Score test in early-stage breast cancer.
- 03In prostate cancer, Artera will present findings on consistent risk stratification using image-only and multimodal AI models.
- 04The studies reinforce MMAI's utility in diverse populations, building on previous validations in various clinical settings.
- 05Artera's platform integrates digitized histopathology images and clinical data to personalize cancer care.
Advertisement
In-Article Ad
At the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Artera will present multiple abstracts showcasing its multimodal artificial intelligence (MMAI) platform. The research focuses on improving risk stratification and treatment decisions in cancer care, particularly in breast and prostate cancer. One key study will validate the MMAI model for predicting chemotherapy benefits in node-positive hormone receptor-positive (HR+) breast cancer, addressing a critical area where treatment uncertainty often exists. Another study will compare MMAI's performance with the 21-gene Recurrence Score test in early-stage breast cancer, demonstrating strong concordance in identifying low-risk patients. Additionally, Artera will present findings on the consistent risk stratification of localized prostate cancer using both image-only and multimodal AI models. These presentations highlight Artera's commitment to enhancing treatment decision-making through advanced AI technology, which has already received FDA clearance and CE marking for its diagnostic tests. Artera's headquarters is located in Los Altos, California, with a clinical laboratory in Jacksonville, Florida.
Advertisement
In-Article Ad
The advancements presented by Artera could significantly enhance treatment options for breast and prostate cancer patients, leading to more personalized care.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the use of AI in cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.